Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Observer-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever YF-17D Vaccine Administered Concomitantly and Sequentially in Healthy Subjects Aged 18 to 60 Years in Non-Endemic Country(Ies)

Trial Profile

A Randomized, Observer-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever YF-17D Vaccine Administered Concomitantly and Sequentially in Healthy Subjects Aged 18 to 60 Years in Non-Endemic Country(Ies)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs TAK 003 (Primary) ; Yellow fever vaccine
  • Indications Dengue
  • Focus Pharmacodynamics; Registrational
  • Sponsors Takeda
  • Most Recent Events

    • 08 Jun 2018 Planned End Date changed from 4 May 2019 to 17 May 2019.
    • 09 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 21 Feb 2018 Planned End Date changed from 17 May 2019 to 4 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top